Innovent Receives Positive CHMP Opinion for its Phase III Drug


Published: 19 Nov 2026

Author: Payal Rabde

Share : linkedin twitter facebook

Innovent Biologics, Inc. announced that it received its first positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The CHMP recommended marketing authorization of Zybrivo (sintilimab), in combination with chemotherapy, for adults with advanced non-squamous non-small cell lung cancer (NSCLC). 

The first positive opinion by the CHMP was backed by the positive results from the Phase III Orient-11 study (NCT03607539). Based on this positive opinion, the European Commission is expected to issue a final decision on marketing authorization in the coming months. If approved, the drug could be marketed across all 27 European Union Member States, along with Iceland, Norway, and Liechtenstein.

What is the ORIENT Study?

ORIENT Phase III study is a randomized, multicenter, double-blind, placebo-controlled trial among 397 adult subjects suffering from locally advanced, metastatic, or recurrent non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations, regardless of programmed death ligand (PD-L1) expression. Subjects were divided randomly into two groups in a 2:1 ratio, receiving sintilimab or placebo, each in combination with pemetrexed and platinum-based chemotherapy.

The study found that the sintilimab plus chemotherapy group demonstrated a 52% reduction in the hazard of disease progression or death and a 35% reduction in the hazard of death compared to placebo with chemotherapy. These results demonstrate the clinical benefit of sintilimab with chemotherapy and its potential to offer an additional first-line treatment option for eligible patients with advanced non-squamous NSCLC in Europe.

About Zybrivo

Zybrivo (sintilimab) is a fully human immunoglobulin G4 (IgG4) monoclonal antibody that binds to programmed cell death-1 (PD-1). This drug can prevent the immune system from attacking cancer cells and blocks their interactions with the ligands PD-L1 and PD-L2.

Expert Opinion

Dr. Hui Zhou, Chief R&D Officer of Oncology, Innovent, commented that the company’s mission is to empower patients worldwide with affordable, high-quality biopharmaceuticals.

The positive CHMP opinion for Zybrivo marks an important regulatory milestone in the company’s international development and brings it a step closer to serving patients in Europe. The company aims to continue advancing the innovative pipeline and work to bring meaningful medicines to patients globally.

About Innovent Biologics

Innovent Biologics, Inc. is a China-based pioneer in first-in-class innovations and develops life-changing medicines. The company’s mission is to empower global patients with affordable, high-quality biopharmaceuticals. Its vision is to be a premier global biopharmaceutical company. With over 15 years of scientific leadership, the company has developed 46 drug candidates and has 20 approved products in China.

Latest News